Compare Aehr Test Systems (AEHR) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aehr Test Systems vs Gilead Sciences, Inc. — how do they compare? Aehr Test Systems trades at $130.3 (market cap $3.82B), while Gilead Sciences, Inc. trades at $136.36 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 44.1× Aehr Test Systems's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Aehr Test Systems pays none. Which is the better fit depends on your goals.
| AEHR | GILD | |
|---|---|---|
Market Cap | $3.82B | $168.35B |
Sector | Technology | Health |
52-Week High | $117.18 | $155.80 |
52-Week Low | $17.38 | $110.56 |
Enterprise Value | $3.72B | $191.42B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEHR Test Systems stock trades at $129.70, up 22.13% in the past 24 hours, with a bullish technical signal from moving averages and strong momentum. Recent earnings beats and a $22 million AI processor order (Accesswire, August 12, 2026) highlight growth potential, though negative net income margins and high P/S of 71.87 reflect valuation concerns amid rapid revenue expansion.
Outlook is mixed: strong AI-driven demand and record bookings support upside, but profitability challenges, insider selling, and customer concentration pose risks. Analyst consensus is cautious with 33% buy ratings, indicating tempered optimism despite technical strength.
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aehr Test Systems
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
